0I1B Stock Overview
Operates as a medical technology company focus on developing clinically differentiated solutions worldwide. More details
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Enovis Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$42.27 |
52 Week High | US$64.85 |
52 Week Low | US$38.55 |
Beta | 2.02 |
1 Month Change | -9.86% |
3 Month Change | -3.21% |
1 Year Change | -25.95% |
3 Year Change | -70.09% |
5 Year Change | -59.78% |
Change since IPO | -65.67% |
Recent News & Updates
Recent updates
Shareholder Returns
0I1B | GB Medical Equipment | GB Market | |
---|---|---|---|
7D | -9.8% | -3.5% | -2.6% |
1Y | -25.9% | -10.6% | 2.4% |
Return vs Industry: 0I1B underperformed the UK Medical Equipment industry which returned -10.6% over the past year.
Return vs Market: 0I1B underperformed the UK Market which returned 2.4% over the past year.
Price Volatility
0I1B volatility | |
---|---|
0I1B Average Weekly Movement | 5.8% |
Medical Equipment Industry Average Movement | 6.5% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 10.6% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0I1B has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0I1B's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 6,550 | Matt Trerotola | www.enovis.com |
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Enovis Corporation Fundamentals Summary
0I1B fundamental statistics | |
---|---|
Market cap | US$2.41b |
Earnings (TTM) | -US$121.38m |
Revenue (TTM) | US$2.00b |
1.2x
P/S Ratio-19.8x
P/E RatioIs 0I1B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0I1B income statement (TTM) | |
---|---|
Revenue | US$2.00b |
Cost of Revenue | US$821.68m |
Gross Profit | US$1.18b |
Other Expenses | US$1.30b |
Earnings | -US$121.38m |
Last Reported Earnings
Sep 27, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.17 |
Gross Margin | 58.95% |
Net Profit Margin | -6.06% |
Debt/Equity Ratio | 40.4% |
How did 0I1B perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 10:30 |
End of Day Share Price | 2024/12/19 00:00 |
Earnings | 2024/09/27 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Enovis Corporation is covered by 35 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jeffrey Johnson | Baird |
null null | Baird |
Robert Cornell | Barclays |